Drug Hunter

JUNE 25, 2023

If the molecule reaches approval, MZE001 could be the first oral therapy for Pompe disease, either alone or in combination with enzyme-replacement therapy. While MZE001’s structure has not been disclosed, an arbitrarily-selected representative example from a recently published patent is highlighted below.

Targeted Protein Degradation 130

Targeted Protein Degradation Computational Chemistry Trials Licensing 130

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

DrugBank

JUNE 27, 2024

Drug repurposing’s potential to target undruggable molecules is showing huge promise for its ability to accelerate the development of new therapies and improve patient outcomes. Repurposing drug combinations expands the possibilities beyond single-drug therapies.

Drugs 98

Drugs Pharma Companies Clinical Trials Computational Chemistry 98

Drug Target Review

MAY 31, 2024

Working at the intersection of medicinal and computational chemistry as an early adopter of integrating in silico tools into the discovery process, I’ve seen first hand the technological advances that have been made over the past five-plus years.

Organic Chemistry 45

Organic Chemistry Computational Chemistry Small Molecule Disease 45

LifeSciVC

APRIL 8, 2025

Nimbus Therapeutics has leveraged modular drug discovery and computational chemistry platforms that align with DARPA- and BARDA-style interests in scalable, rapid-response therapeutic development. And at the foundation are the supply chain dynamics: how therapies are stored, transported, and accessed across geographies.

RNA 40

RNA Packaging Computational Chemistry Science 40